Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 6, Pages 2353-2371Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01612
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [21572230, 81425021, 81673285]
- Guangdong Province [2014TQ01R341, 2015A030306042, 2015A030312014, 2016A050502041]
- Guangzhou City [201508030036]
- Jinan University
Ask authors/readers for more resources
Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, 3bw, potently inhibits CSF1R kinase with an IC50 value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of 3bw was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound 3bw may serve as a new valuable lead compound for future anticancer drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available